blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2914627

EP2914627 - ANTI-CD40 ANTIBODIES AND METHODS OF USE [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  11.02.2022
Database last updated on 30.11.2024
FormerThe patent has been granted
Status updated on  05.03.2021
FormerGrant of patent is intended
Status updated on  20.10.2020
FormerExamination is in progress
Status updated on  22.02.2017
Most recent event   Tooltip06.09.2024Lapse of the patent in a contracting state
New state(s): MT		published on 09.10.2024  [2024/41]
Applicant(s)For all designated states
Apexigen, Inc.
75 Shoreway Road, Suite C
San Carlos, CA 94070 / US
[2018/49]
Former [2015/37]For all designated states
Apexigen, Inc.
863 Mitten Road, Suite 103
Burlingame, California 94070 / US
Inventor(s)01 / ZHANG, Yongke
119 Stockton Place
Palo Alto, California 94303 / US
02 / YU, Guo-Liang
1025 Tournament Drive
Hillsborough, California 94010 / US
03 / ZHU, Weimin
1216 Toyon Drive
Millbrae CA 94030 / US
 [2021/14]
Former [2015/37]01 / ZHANG, Yongke
119 Stockton Place
Palo Alto, California 94303 / US
02 / YU, Guo-Liang
1025 Tournament Drive
Hillsborough, California 94010 / US
03 / ZHU, Weimin
1870 40th Avenue
San Francisco, California 94122 / US
Representative(s)Schiweck Weinzierl Koch Patentanwälte Partnerschaft mbB
Ganghoferstraße 68 B
80339 München / DE
[2021/14]
Former [2015/37]Schiweck, Weinzierl & Koch
European Patent Attorneys
Landsberger Straße 98
80339 München / DE
Application number, filing date13786884.030.10.2013
[2015/37]
WO2013US67583
Priority number, dateUS201261720289P30.10.2012         Original published format: US 201261720289 P
[2015/37]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2014070934
Date:08.05.2014
Language:EN
[2014/19]
Type: A1 Application with search report 
No.:EP2914627
Date:09.09.2015
Language:EN
The application published by WIPO in one of the EPO official languages on 08.05.2014 takes the place of the publication of the European patent application.
[2015/37]
Type: B1 Patent specification 
No.:EP2914627
Date:07.04.2021
Language:EN
[2021/14]
Search report(s)International search report - published on:EP08.05.2014
ClassificationIPC:C07K16/28, A61K39/00
[2015/37]
CPC:
C07K16/2878 (EP,US); A61P29/00 (EP); A61P35/00 (EP);
A61P35/02 (EP); A61P37/00 (EP); A61P37/02 (EP);
A61K2039/505 (EP,US); A61K2039/545 (EP,US); C07K2317/24 (EP,US);
C07K2317/34 (EP,US); C07K2317/73 (EP,US); C07K2317/732 (EP,US);
C07K2317/75 (EP,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2015/37]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:ANTI-CD40-ANTIKÖRPER UND VERFAHREN ZUR VERWENDUNG[2015/37]
English:ANTI-CD40 ANTIBODIES AND METHODS OF USE[2015/37]
French:ANTICORPS ANTI-CD40 ET PROCÉDÉS D'UTILISATION[2015/37]
Entry into regional phase18.05.2015National basic fee paid 
18.05.2015Designation fee(s) paid 
18.05.2015Examination fee paid 
Examination procedure18.05.2015Amendment by applicant (claims and/or description)
18.05.2015Examination requested  [2015/37]
13.10.2016Despatch of a communication from the examining division (Time limit: M04)
21.02.2017Reply to a communication from the examining division
24.07.2017Despatch of a communication from the examining division (Time limit: M06)
05.01.2018Reply to a communication from the examining division
29.11.2018Despatch of a communication from the examining division (Time limit: M04)
15.01.2019Reply to a communication from the examining division
21.10.2020Communication of intention to grant the patent
26.02.2021Fee for grant paid
26.02.2021Fee for publishing/printing paid
26.02.2021Receipt of the translation of the claim(s)
Divisional application(s)EP21166914.8  / EP3925977
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  13.10.2016
Opposition(s)10.01.2022No opposition filed within time limit [2022/11]
Fees paidRenewal fee
12.10.2015Renewal fee patent year 03
11.10.2016Renewal fee patent year 04
11.10.2017Renewal fee patent year 05
11.10.2018Renewal fee patent year 06
15.10.2019Renewal fee patent year 07
14.10.2020Renewal fee patent year 08
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU30.10.2013
AL07.04.2021
AT07.04.2021
CY07.04.2021
CZ07.04.2021
EE07.04.2021
FI07.04.2021
HR07.04.2021
LT07.04.2021
LV07.04.2021
MK07.04.2021
MT07.04.2021
PL07.04.2021
RO07.04.2021
RS07.04.2021
SI07.04.2021
SK07.04.2021
SM07.04.2021
BG07.07.2021
GR08.07.2021
IS07.08.2021
PT09.08.2021
[2024/41]
Former [2024/22]HU30.10.2013
AL07.04.2021
AT07.04.2021
CY07.04.2021
CZ07.04.2021
EE07.04.2021
FI07.04.2021
HR07.04.2021
LT07.04.2021
LV07.04.2021
MK07.04.2021
PL07.04.2021
RO07.04.2021
RS07.04.2021
SI07.04.2021
SK07.04.2021
SM07.04.2021
BG07.07.2021
GR08.07.2021
IS07.08.2021
PT09.08.2021
Former [2023/30]HU30.10.2013
AL07.04.2021
AT07.04.2021
CY07.04.2021
CZ07.04.2021
EE07.04.2021
FI07.04.2021
HR07.04.2021
LT07.04.2021
LV07.04.2021
PL07.04.2021
RO07.04.2021
RS07.04.2021
SI07.04.2021
SK07.04.2021
SM07.04.2021
BG07.07.2021
GR08.07.2021
IS07.08.2021
PT09.08.2021
Former [2023/28]HU30.10.2013
AL07.04.2021
AT07.04.2021
CZ07.04.2021
EE07.04.2021
FI07.04.2021
HR07.04.2021
LT07.04.2021
LV07.04.2021
PL07.04.2021
RO07.04.2021
RS07.04.2021
SI07.04.2021
SK07.04.2021
SM07.04.2021
BG07.07.2021
GR08.07.2021
IS07.08.2021
PT09.08.2021
Former [2022/29]AL07.04.2021
AT07.04.2021
CZ07.04.2021
EE07.04.2021
FI07.04.2021
HR07.04.2021
LT07.04.2021
LV07.04.2021
PL07.04.2021
RO07.04.2021
RS07.04.2021
SI07.04.2021
SK07.04.2021
SM07.04.2021
BG07.07.2021
GR08.07.2021
IS07.08.2021
PT09.08.2021
Former [2022/26]AL07.04.2021
AT07.04.2021
CZ07.04.2021
EE07.04.2021
FI07.04.2021
HR07.04.2021
LT07.04.2021
LV07.04.2021
PL07.04.2021
RO07.04.2021
RS07.04.2021
SK07.04.2021
SM07.04.2021
BG07.07.2021
GR08.07.2021
IS07.08.2021
PT09.08.2021
Former [2022/23]AT07.04.2021
CZ07.04.2021
EE07.04.2021
FI07.04.2021
HR07.04.2021
LT07.04.2021
LV07.04.2021
PL07.04.2021
RO07.04.2021
RS07.04.2021
SK07.04.2021
SM07.04.2021
BG07.07.2021
GR08.07.2021
IS07.08.2021
PT09.08.2021
Former [2022/10]AT07.04.2021
CZ07.04.2021
EE07.04.2021
FI07.04.2021
HR07.04.2021
LT07.04.2021
LV07.04.2021
PL07.04.2021
RO07.04.2021
RS07.04.2021
SK07.04.2021
SM07.04.2021
BG07.07.2021
GR08.07.2021
PT09.08.2021
IS22.12.2021
Former [2022/09]AT07.04.2021
CZ07.04.2021
FI07.04.2021
HR07.04.2021
LT07.04.2021
LV07.04.2021
PL07.04.2021
RO07.04.2021
RS07.04.2021
SK07.04.2021
SM07.04.2021
BG07.07.2021
GR08.07.2021
IS07.08.2021
PT09.08.2021
Former [2022/07]AT07.04.2021
FI07.04.2021
HR07.04.2021
LT07.04.2021
LV07.04.2021
PL07.04.2021
RS07.04.2021
SM07.04.2021
BG07.07.2021
GR08.07.2021
IS07.08.2021
PT09.08.2021
Former [2021/52]AT07.04.2021
FI07.04.2021
HR07.04.2021
LT07.04.2021
LV07.04.2021
PL07.04.2021
RS07.04.2021
BG07.07.2021
GR08.07.2021
IS07.08.2021
PT09.08.2021
Former [2021/51]AT07.04.2021
FI07.04.2021
HR07.04.2021
LT07.04.2021
LV07.04.2021
RS07.04.2021
BG07.07.2021
GR08.07.2021
IS07.08.2021
PT09.08.2021
Former [2021/50]AT07.04.2021
FI07.04.2021
HR07.04.2021
LT07.04.2021
LV07.04.2021
BG07.07.2021
GR08.07.2021
PT09.08.2021
Former [2021/49]AT07.04.2021
FI07.04.2021
HR07.04.2021
LT07.04.2021
LV07.04.2021
BG07.07.2021
GR08.07.2021
Former [2021/47]AT07.04.2021
FI07.04.2021
LT07.04.2021
BG07.07.2021
Former [2021/46]AT07.04.2021
FI07.04.2021
LT07.04.2021
Cited inInternational search[X]WO9517202  (IMMUNEX CORP [US]);
 [X]WO03040170  (PFIZER PROD INC [US], et al);
 [A]WO2006128103  (SEATTLE GENETICS INC [US], et al);
 [XP]WO2012149356  (APEXIGEN INC [US], et al);
ExaminationUS5182368
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.